These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31807115)

  • 1. Clinical-biological characteristics and treatment outcomes of pediatric pro-B ALL patients enrolled in BCH-2003 and CCLG-2008 protocol: a study of 121 Chinese children.
    Gao C; Liu SG; Yue ZX; Liu Y; Liang J; Li J; Zhang YY; Yu JL; Wu Y; Lin W; Zheng HY; Zhang RD
    Cancer Cell Int; 2019; 19():293. PubMed ID: 31807115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of the efficacy of two chemotherapy protocols for children with TEL-AML1[STBZ] fusion gene positive acute lymphoblastic leukemia].
    Wang KL; Mei YY; Cui L; Gao C; Liu FF; Zhao XX; Li WJ; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Wu MY; Zhou X; Li ZG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):285-90. PubMed ID: 24762993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
    Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
    BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of immunophenotypic markers in pediatric T-cell acute lymphoblastic leukemia.
    Sidhom I; Shaaban K; Soliman S; Ezzat S; El-Anwar W; Hamdy N; Yassin D; Salem S; Hassanein H; Mansour MT
    J Egypt Natl Canc Inst; 2008 Jun; 20(2):111-20. PubMed ID: 20029466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics and prognostic analysis of pediatric pro-B cell acute lymphoblastic leukemia].
    Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
    Zhongguo Dang Dai Er Ke Za Zhi; 2020 Dec; 22(12):1286-1294. PubMed ID: 33327999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective evaluation of minimal residual disease as risk stratification for CCLG-ALL-2008 treatment protocol in pediatric B precursor acute lymphoblastic leukemia.
    Hu YX; Lu J; He HL; Wang Y; Li JQ; Xiao PF; Li J; Lv H; Sun YN; Fan JJ; Chai YH; Hu SY
    Eur Rev Med Pharmacol Sci; 2016 May; 20(9):1680-90. PubMed ID: 27212157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
    Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
    Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, biological, and outcome features of P2RY8-CRLF2 and CRLF2 over-expression in pediatric B-cell precursor acute lymphoblastic leukemia according to the CCLG-ALL 2008 and 2018 protocol.
    Wang Y; Li J; Xue TL; Tian S; Yue ZX; Liu SG; Gao C
    Eur J Haematol; 2023 Jun; 110(6):669-679. PubMed ID: 36814093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical Characteristics and Treatment Efficacy of Children with SIL/TAL1 Positive T-Cell Acute Lymphoblastic Leukemia].
    Liu X; Li WJ; Zhao XX; Gao C; Zhao W; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Cui L; Li ZG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):681-6. PubMed ID: 27342490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
    Mei YY; Gao C; Cui L; Zhao XX; Zhao W; Li WJ; Wang KL; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Li ZG
    Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):467-71. PubMed ID: 24120066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NOTCH1 mutations are associated with favourable long-term prognosis in paediatric T-cell acute lymphoblastic leukaemia: a retrospective study of patients treated on BCH-2003 and CCLG-2008 protocol in China.
    Gao C; Liu SG; Zhang RD; Li WJ; Zhao XX; Cui L; Wu MY; Zheng HY; Li ZG
    Br J Haematol; 2014 Jul; 166(2):221-8. PubMed ID: 24690100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
    Baraka A; Sherief LM; Kamal NM; Shorbagy SE
    Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients.
    Gao C; Zhao XX; Li WJ; Cui L; Zhao W; Liu SG; Yue ZX; Jiao Y; Wu MY; Li ZG
    Am J Hematol; 2012 Nov; 87(11):1022-7. PubMed ID: 22911440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NG2 Molecule Expression in Acute Lymphoblastic Leukemia B Cells: A Flow-Cytometric Marker for the Rapid Identification of
    Bisegna ML; Peragine N; Elia L; Matarazzo M; Milani ML; Intoppa S; Di Trani M; Malfona F; Martelli M; De Propris MS
    Mediterr J Hematol Infect Dis; 2024; 16(1):e2024018. PubMed ID: 38468826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
    Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Expression of Interleukin-3 Receptor Alpha Chain (CD123) Predicts Favorable Outcome in Pediatric B-Cell Acute Lymphoblastic Leukemia Lacking Prognosis-Defining Genomic Aberrations.
    Li Z; Chu X; Gao L; Ling J; Xiao P; Lu J; Wang Y; He H; Li J; Hu Y; Li J; Pan J; Xiao S; Hu S
    Front Oncol; 2021; 11():614420. PubMed ID: 33796456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.
    Stutterheim J; de Lorenzo P; van der Sluis IM; Alten J; Ancliffe P; Attarbaschi A; Aversa L; Boer JM; Biondi A; Brethon B; Diaz P; Cazzaniga G; Escherich G; Ferster A; Kotecha RS; Lausen B; Leung AW; Locatelli F; Silverman L; Stary J; Szczepanski T; van der Velden VHJ; Vora A; Zuna J; Schrappe M; Valsecchi MG; Pieters R
    Eur J Cancer; 2022 Jan; 160():72-79. PubMed ID: 34785111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.